To explore the role of retinal biomarkers in guiding treatment decisions for diabetic macular edema (DME), emphasizing the importance of personalized treatment strategies.
Key Findings:
Improvement in DRIL is associated with better visual outcomes.
Disorganization of outer retinal layers correlates with poorer response to anti-VEGF therapy.
Presence of cystoid macular edema predicts greater CST reduction after anti-VEGF treatment.
Absence of HRF is linked to improved visual outcomes post anti-VEGF therapy.
Interpretation:
Imaging biomarkers can enhance the understanding of treatment responses in DME, allowing for more personalized management strategies.
Limitations:
Direct comparisons between treatment modalities are limited, impacting the ability to choose the most effective treatment.
Structural improvements do not always correlate with visual function enhancements, complicating treatment assessments.
Conclusion:
Retinal biomarkers derived from advanced imaging techniques can significantly inform treatment selection and improve outcomes for patients with DME, underscoring the potential for personalized management strategies.
